The first trial in the C.R. Bard Inc. Pelvic Repair System Products Liability Litigation (MDL 2187) has been set to start on February 5, 2013. To date, 600 lawsuits naming Bard Avaulta transvaginal mesh products are pending in the litigation in the U.S. District Court for the Southern District of West Virginia. The date for the first Bard Avaulta transvaginal mesh trial was set by U.S. District Judge Joseph R. Goodwin in an Order dated May 1, 2012. [wvsd.uscourts.gov/mdl/2187/pdfs/PTO_35.pdf], according to a report in Bloomberg Business Week late last week.
Judge Goodwin is overseeing three other transvaginal mesh device MDLs, including those manufactured by American Medical Systems, Inc. (MDL No. 2325), Boston Scientific Corp. (MDL No. 2326) and Ethicon, Inc., a unit of Johnson & Johnson (MDL No. 2327). Verdicts in these trendsetting trials will help gauge how juries might decide their verdicts in similar transvaginal mesh lawsuits pending in the Bard Avaulta litigation.
All of the lawsuits pending in the litigations allege that the transvaginal mesh devices used in pelvic organ prolapse (POP) and stress urinary incontinence (SUI) repair surgeries caused women to suffer serious complications, including vaginal erosion, inflammation, infection, chronic pain and organ damage.